Immune Response Affecting Drug Patents (Class 514/885)
-
Patent number: 5776966Abstract: Treatment with a set of porphyrin compounds using a photodynamic therapy approach is able selectively to lower elevated levels of activated leukocytes in a leukocyte population. This is particularly helpful in subjects containing such elevated levels of T-cell subsets, such as HIV-infected subjects.Type: GrantFiled: May 27, 1992Date of Patent: July 7, 1998Assignees: University of British Columbia, Quadra Logic Technologies Inc.Inventor: Janice North
-
Patent number: 5773425Abstract: Methods for the treatment of sarcoma, carcinoma and lymphoma in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative.Type: GrantFiled: June 5, 1995Date of Patent: June 30, 1998Assignee: Carrington Laboratories, Inc.Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
-
Patent number: 5773603Abstract: The present invention relates to adenosinedeaminase inhibitors containing at least one O-alkylated moiety derivative and the pharmaceutically acceptable salts thereof. The pharmaceutical compositions of the present invention include adenosinedeaminase inhibitors containing at least one of the compounds represented by Formula (I): ##STR1## wherein each of R.sub.1, R.sub.2, and R.sub.3 are the same or different and is hydrogen or alkyl;R is hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkynyl, alkoxy, phenyl, hydroxy, amino, alkylamino, phenylamino or halogen;X is hydrogen, alkyl, alkynyl, allyl, methallyl, cycloalkyl, alkyl having one or more hydroxy groups, phenyl, substituted phenyl, alkyl having one or more phenyl groups, alkyl having one or more substituted phenyl groups, bicycloalkyl, naphthylalkyl, acenaphthylenylalkyl or a compound represented by Formula (II) or Formula (III) ##STR2## wherein Z is hydrogen, hydroxy or lower alkoxy;Q is hydrogen or hydroxy;A is --CH.sub.Type: GrantFiled: May 30, 1995Date of Patent: June 30, 1998Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Toshio Yamada
-
Patent number: 5770234Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.Type: GrantFiled: December 13, 1996Date of Patent: June 23, 1998Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Girish Giridhar
-
Patent number: 5770578Abstract: The use of triterpensaponins, like notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for the production of medicaments for stimulating the fibrinolytic activity and blocking the endotoxin effect, especially for the treatment of patients and animals which suffer from endotoxin shock or to limit the endotoxin shock. Corresponding medicaments are also suitable prophylactive and therapeutic treatment of patients of coronary heart disease, peripheral arterial disease for patients who suffer from angina pectoris and for the prevention of such diseases in healthy persons.Type: GrantFiled: January 4, 1996Date of Patent: June 23, 1998Assignee: Bergi GmbHInventors: Bernd Binder, Weijian Zhang, Johann Wojta
-
Patent number: 5767065Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.Type: GrantFiled: June 6, 1995Date of Patent: June 16, 1998Assignee: Immunex CorporationInventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
-
Patent number: 5763417Abstract: The use of dsRNA for use in the reactivation of natural defense systems within human cells, tissues and organs reduced to inadequate function subsequent to injury. Specific treatments for various clinical phases of the biological continuous of an acquired immune deficient state are described. Protection from the toxic effects associated with increased TNF levels is described.Type: GrantFiled: June 6, 1995Date of Patent: June 9, 1998Assignee: Hemispherx Biopharma, Inc.Inventor: Leo Einck
-
Patent number: 5763420Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.Type: GrantFiled: May 25, 1995Date of Patent: June 9, 1998Assignee: MECT CorporationInventors: Ryoichi Osawa, Isao Suda, Masaaki Numata, Mamoru Sugimoto, Kenkichi Tomita, Nobuyuki Kibushi, Takayuki Ishii, Naokazu Sugiyama, Makiko Kasano, Tae Yasunaga, Makoto Tanaka, Tomoya Ogawa, Mariko Ishii
-
Patent number: 5763582Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.Type: GrantFiled: June 6, 1995Date of Patent: June 9, 1998Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5762935Abstract: The uses of lignans of the sesamin family to treat infection and inflammation is disclosed. These lignans may be delivered enterally or parenterally and either in the form of sesame oil or in purified form. A total parenteral nutrition solution or dietary supplement are the preferred forms of administration.Type: GrantFiled: April 26, 1995Date of Patent: June 9, 1998Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: R. Armour Forse, Sambasiva Chavali
-
Patent number: 5760013Abstract: Novel thymidylate analogs having the following formula are synthesized in the present invention, which are found active against human immunodeficiency virus type 1 (HIV-1): ##STR1## wherein R.sup.1 is hydrogen, cyano (--CN), halogen or azido (--N.sub.3); R.sup.2 is hydroxyl or an amino ester radical having a formula of --NHR.sup.4 COOR.sup.5, wherein R.sup.4 is a bivalent C.sub.1 -C.sub.4 saturated hydrocarbon and R.sup.5 is C.sub.1 -C.sub.4 alkyl; Me is methyl; and R.sup.Type: GrantFiled: August 21, 1996Date of Patent: June 2, 1998Assignee: National Science CouncilInventors: Jih Ru Hwu, Gholam H. Hakimelahi, Shwu-Chen Tsay
-
Patent number: 5759550Abstract: An improved method for suppressing xenograft rejection in a host subject is disclosed. The method includes administering an immunosuppressant drug, where the drug or the amount of drug administered is, by itself, ineffective to suppress xenograft rejection. Effective xenograft suppression is achieved by also administering an ethanolic extract of Triterygium wilfordii or a purified triptolide component thereof.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignee: Pharmagenesis, Inc.Inventors: Tien Wen Tao Wiedmann, Jian Wang
-
Patent number: 5759992Abstract: An immunotherapeutic agent is prepared from cells of E. coli or members of the genus Mycobacterium. The material is effective as an anti-tumor agent, an immunostimulant, and an adjuvant. Also disclosed is a method of evoking an immunostimulatory response through the activation of the RAS gene.Type: GrantFiled: March 7, 1996Date of Patent: June 2, 1998Assignee: David PlattInventor: David Platt
-
Patent number: 5759533Abstract: Peptides having the amino acid sequence ##STR1## wherein X is H, Asp-Leu-Tyr-, Ser-Asp-Leu-Tyr- or Asp-Ser-Asp-Leu-Tyr-. The peptide wherein X is H is human neutrophil-activating peptide-2 (hNAP-2) and those wherein X is other than H are natural variants thereof. The peptides have neutrophil-stimulating activity, are structurally related to NAF/NAP-1, .beta.-thromboglobulin, PBP and CTAP-III and may be isolated from leukocytes and platelets and synthesized by standard peptide synthesis processes and recombinant DNA techniques.Type: GrantFiled: June 6, 1995Date of Patent: June 2, 1998Assignees: Novartis AG, Theodor Kocher InstitutInventors: Marco Baggiolini, Kenneth John Clemetson, Alfred Walz
-
Patent number: 5756477Abstract: The invention relates to a method of treating and a therapeutical composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS) and related infections. The composition comprises from 1 to 100% of a complex of Poly(A).Poly(U), preferably associated with other anti-AIDS coagents which act on the HIV virus according to a different mechanism from that of the complex of Poly(A).Poly(U). The composition is suitably administered in 100 to 4,000 mg doses and at 3 to 5 day intervals.Type: GrantFiled: January 4, 1996Date of Patent: May 26, 1998Assignee: Societe de Conseils de Recherches Et D'Applications ScientifiquesInventors: Ara G. Hovanessian, Evelyne Deschamps De Paillette
-
Patent number: 5756718Abstract: Disclosed are lipid A analogs useful for the treatment of septic shock and LPS-mediated activation of viral infection.Type: GrantFiled: June 7, 1995Date of Patent: May 26, 1998Assignee: Eisai Co., Ltd.Inventors: William J. Christ, Lynn D. Hawkins, Tsutomu Kawata, Daniel P. Rossignol, Seiichi Kobayashi, Osamu Asano
-
Patent number: 5756482Abstract: A method is disclosed for attenuation of nervous system damage after injury which comprises administering therapeutic amounts of PREG, PREG-S, or esters of PREG or PREG-S together with an enhancer of secretory processes in non-neural cells such as a bacterial lipopolysaccharide and a non-steroidal antiinflammatory substance such as indomethacin.Type: GrantFiled: May 16, 1996Date of Patent: May 26, 1998Assignee: The Center for Innovative TechnologyInventors: Eugene Roberts, Lloyd Guth
-
Patent number: 5753695Abstract: The invention relates to a compound of formula (I) ##STR1## wherein X is a pharmacologically acceptable anion,R.sub.1 and R.sub.2 are independently of each other hydrogen, or an --OY group in which Y is hydrogen, an .alpha.-aminoacyl, or a C.sub.1-5 aminoalkyl residue,R.sub.3, R.sub.4 and R.sub.7 are independently of each other hydrogen, or a C.sub.1-5 alkyl residueR.sub.5 is hydrogen, and .alpha.-aminoacyl, or a C.sub.1-5 alkyl residue, andR.sub.6 is hydrogen, OH.sup.-, or a C.sub.1-5 alkyl residue,and pharmaceutically acceptable salts and esters thereof; and to condensation processes for preparing them.Type: GrantFiled: May 19, 1994Date of Patent: May 19, 1998Assignee: Biogal Gyogyszergyar RTInventors: Gyorgy Sulyok, Janos Balint, Ildiko Borbely, Jolan Kiss, Ferenc D. Toth
-
Patent number: 5750503Abstract: The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.Type: GrantFiled: May 5, 1995Date of Patent: May 12, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Gottfried Alber, Peter Angehrn
-
Patent number: 5747462Abstract: The present invention relates to the area of pharmacology; its objective is to solve the technical problem of inflammation, pain, pruritus and local hyperthermia in human beings and animal species. The composition and the subcompositions thereof are obtained from plants of the family Cactaceae, the main methodological steps being a set of processes: production, purification, physicochemical quantification, biotherapeutic evaluation, biopharmaceutical formulation and molecular identification. From the molecular identification a set of molecules is recognized, comprising carbohydrates and an aromatic amine, the general formulae of which are:C.sub.5 H.sub.10 O.sub.5 (RIBOSE),C.sub.6 H.sub.12 O.sub.5 (FUCOSE),C.sub.6 H.sub.12 O.sub.6 (GALACTOSE; MANNOSE; GLUCOSE),C.sub.8 H.sub.11 O.sub.2 N (1-HYDROXY-1-(4-HYDROXYPHENYL)-2-AMINOETHANE),C.sub.10 H.sub.18 O.sub.9 (RIBOFURANOSYLRIBOSE).Type: GrantFiled: August 16, 1995Date of Patent: May 5, 1998Assignee: Laboratorio CHile S.A.Inventor: Victoria M. Fuentes
-
Patent number: 5747035Abstract: Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life. Methods are described herein which utilize these polypeptides in treating disorders involving the LFA-1 receptor. In one of the described methods of treatment, the polypeptide includes the amino acid sequence PKNSSMISNTP (SEQ ID NO:3) and may also include the sequence selected from the group consisting of HQNLSDGK (SEQ ID NO: 1), HQNISDGK (SEQ ID NO:2), HQSLGTQ (SEQ ID NO:11) and VISSHLGQ (SEQ ID NO:31).Type: GrantFiled: April 14, 1995Date of Patent: May 5, 1998Assignee: Genentech, Inc.Inventors: Leonard G. Presta, Bradley R. Snedecor
-
Patent number: 5747024Abstract: Methods of enhancing a mammal's immune response to a vaccine antigen are disclosed. Interleukin-15 can be used as a vaccine adjuvant to enhance or potentiate the immune response to a vaccine. Compositions comprising an immunogenic amount of vaccine antigen and an immunogenicity-augmenting amount of IL-15 are also provided by the invention. IL-15 can be used alone in the invention or in concurrent or sequential combination with additional vaccine adjuvants.Type: GrantFiled: July 19, 1995Date of Patent: May 5, 1998Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Michael B. Widmer
-
Patent number: 5747461Abstract: This invention discloses a method of using fructose-1,6-diphosphate (FDP) to help suppress the rejection of internal organs such as kidneys, hearts, etc. At least three major advantages of FDP in conjunction with organ transplants have been identified: (1) FDP can help reduce the unwanted proliferation of certain types of stimulated lymphocytes which would otherwise pose a risk of attacking the non-self cells in the transplanted organ; (2) FDP can also potentiate the effectiveness of cyclosporine as a transplant-protecting immunosuppressant, thereby allowing a reduction in CSA dosages, which in turn can reduce the likelihood and the severity of toxic side effects and other dangers of CSA treatment; (3) FDP can also reduce the amount of damage inflicted on an organ during the removal and storage steps required in organ transplantation.Type: GrantFiled: July 26, 1994Date of Patent: May 5, 1998Inventor: Angel K. Markov
-
Patent number: 5747040Abstract: The present invention is directed to methods of suppressing inflammatory responses, inducing tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis, by the administration of lectin derived carbohydrate binding peptides or derivatives thereof, in particular, peptides capable of binding terminally linked .alpha.-sialic acid(2.fwdarw.6).beta.Gal- and/or .alpha.-sialic acid(2.fwdarw.3).beta.Gal- groups on structures or molecules comprising such groups. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides or derivatives thereof are also disclosed.Type: GrantFiled: February 17, 1995Date of Patent: May 5, 1998Assignee: Alberta Research CouncilInventors: Louis D. Heerze, Glen D. Armstrong, Richard Smith
-
Patent number: 5744461Abstract: Lipid-containing prodrugs are provided for treating viral infections due to herpes, influenza, hepatitis B, Epstein-Barr, and varicella zoster viruses, as well as cytomegalovirus and derivatives of antiviral agents. The compounds comprise phosphonoacids having antiviral activity which are linked, either through the phosphate group or carboxyl group of the phosphonoacid, to one of a selected group of lipids. Phosphonoacetic acid and phosphonoformic acid are thus linked to phospholipids, glycerolipids, sphingolipids, glycolipids, or fatty acids. The compounds persist, after intracellular hydrolysis, as the antiviral phosphonoacids. The lipid prodrugs are effective in improving the efficacy of antiviral phosphonoacids by prolonging their antiviral activity following administration.Type: GrantFiled: May 26, 1995Date of Patent: April 28, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Karl Y. Hostetler, Raj Kumar
-
Patent number: 5739300Abstract: The invention relates to conjugates which consist of mono- or polycarboxylated piperidine or pyrrolidine derivatives and pyranoses, furanoses or polyalcohols linked via a chain or a cyclic system. The carboxyl groups of the piperidine derivatives can either be located directly on the ring or linked to the ring via a short chain. The invention additionally relates to the preparation of these compounds and to their use for the production of pharmaceuticals and diagnostics.Type: GrantFiled: October 4, 1996Date of Patent: April 14, 1998Assignee: Hoechst AktiengesellschaftInventors: Alexander Toepfer, Gerhard Kretzschmar, Bernward Scholkens, Peter Klemm, Christoph Huls, Dirk Seiffge
-
Patent number: 5736533Abstract: The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc--;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.Type: GrantFiled: June 7, 1995Date of Patent: April 7, 1998Assignee: Neose Technologies, Inc.Inventors: Paul M. Simon, David Zopf, Roger A. Barthelson, Karl F. Johnson
-
Patent number: 5736143Abstract: The present invention is directed to methods of suppressing inflammatory responses, including tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis, by the administration of lectin derived carbohydrate binding peptides or derivatives thereof, in particular, peptides capable of binding terminally linked .alpha.-sialic acid (2.fwdarw.6).beta.Gal- and/or .alpha.-sialic acid(2.fwdarw.3).beta.Gal-groups on structures or molecules comprising such groups. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides or derivatives thereof are also disclosed.Type: GrantFiled: February 17, 1995Date of Patent: April 7, 1998Assignee: Alberta Research CouncilInventors: Louis D. Heerze, Glen D. Armstrong, Richard Smith
-
Patent number: 5733881Abstract: Compounds of the formula I as well as methods for their preparation, their pharmaceutical preparations and their use. ##STR1## The compounds of formula I are useful in therapy, especially as analgesics and as immunosuppresive agents.Type: GrantFiled: August 22, 1995Date of Patent: March 31, 1998Assignee: Astra ABInventor: Peter Schiller
-
Patent number: 5728685Abstract: Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues;R.sup.3 is a negatively charged moiety including SO.sub.4.sup.2-, PO.sub.4.sup.2-, or related group;Y is H or lower alkyl (1-4C); andX is H or --CHR.sup.4 (CHOR.sup.1).sub.2 CHR.sup.5 OR.sup.1 wherein R.sup.4 and R.sup.5 are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;said five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R.sup.1, CH.sub.2 OR.sup.1, OR.sup.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignee: Glycomed IncorporatedInventors: Saeed A. Abbas, Falguni Dasgupta, Darwin Asa, John H. Musser, Mina A. Nashed
-
Patent number: 5728721Abstract: The use of compound 1 and/or 2 of the formulae ##STR1## and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.Type: GrantFiled: August 20, 1992Date of Patent: March 17, 1998Assignee: Hoechst AktiengesellschaftInventor: Robert Ryder Bartlett
-
Patent number: 5725850Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.Type: GrantFiled: January 11, 1995Date of Patent: March 10, 1998Assignee: Chiron CorporationInventors: Peter Ralph, Kong T. Chong, James Devlin, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring, Sylvia Hsieh Ma
-
Patent number: 5723120Abstract: This invention provides a class of interleukin-6 (IL-6) muteins which act as IL-6 receptor antagonists, thereby inhibiting the normal function of naturally-occurring IL-6. These IL-6 receptor antagonism are preferably IL-6 molecules containing one or more mutations in the Site II region comprising amino acids 154-163. This invention also provides pharmaceutical compositions comprising IL-6 receptor antagonists with a pharmaceutically acceptable carrier. This invention further provides methods for treating IL-6 related diseases such as sepsis and multiple myeloma, the methods comprising administering to a patient an IL-6 receptor antagonist.Type: GrantFiled: June 7, 1995Date of Patent: March 3, 1998Assignees: Chiron Corporation, Central Laboratory of the Netherlands Red Cross Blood Transfusion ServiceInventors: Just P. J. Brakenhoff, Lucien A. Aarden
-
Patent number: 5723504Abstract: Novel Amadori reaction compounds have the formula R.sub.1 --NH--R.sub.2, wherein R.sub.1 comprises the D-form of a 1-amino-1-deoxy-2-ketose radical derived from a sugar radical selected from the group of glucose, xylose, galactose, rhamnose, fructose, mannose, 6-deoxyglucose, glucosamine and galactosamine, and R.sub.2 comprises the L-form of an aminoacid or peptide radical selected from the group of serine, glycine, proline, histidine, arginine, alanine, aspartic acid, glutamic acid, phenylalanine, treonine, cysteine, cystine, glutamine, asparagine, methionine, tyrosine, hydroxyproline, tryptophane, valine isoleucine, lysine and leucine. Compounds and combinations of compounds having the general formula R.sub.1 '--NH--R.sub.2 ', wherein R.sub.1 ' comprises a 1-amino-1-deoxy-2-ketose radical derived from the group of simple sugars, oligo- and polysaccharides, and R.sub.Type: GrantFiled: October 24, 1994Date of Patent: March 3, 1998Assignee: Torf EstablishmentInventors: Jan Zbigniew Mioduszewski, Krystyna Witkiewicz, Anna Inglot
-
Patent number: 5721103Abstract: Novel trienoic compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.Type: GrantFiled: June 7, 1995Date of Patent: February 24, 1998Assignee: Ligand Pharmaceuticals IncorporatedInventors: Marcus F. Boehm, Lin Zhang, Youssef L. Bennani, Alex M. Nadzan
-
Patent number: 5720952Abstract: A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises:preparing RNA from a cell that produces CSF;preparing polyadenylated messenger RNA from the RNA;preparing single stranded cDNA from the messenger RNA;converting the single stranded cDNA to double stranded cDNA;inserting the double stranded cDNA into transformation vectors and transforming bacteria with the vector to form colonies;picking pools of 200 to 500 colonies each and isolating plasmid DNA from each pool;transfecting the plasmid DNA into suitable host cells for expressing CSF protein;culturing the transfected cells and assaying the supernatant for CSF activity; andselecting CSF positive pools and screening the colonies used to make the pool to identify a colony having CSF activity. Also described are a cDNA coding for a protein having CSF activity (i.e.Type: GrantFiled: June 6, 1995Date of Patent: February 24, 1998Assignee: Novartis CorporationInventors: Steven C. Clark, Randal J. Kaufman, Gordon C. Wong
-
Patent number: 5721206Abstract: A pharmaceutical composition for use as a retinal pigment epithelial cell growth stimulating agent comprising an interferon and a pharmaceutically acceptable carrier is disclosed. The composition is useful as a therapeutic agent for oculopathies, such as pigmentary retinal degeneration, central chorioretinopathy, and macular dystrophy.Type: GrantFiled: March 15, 1995Date of Patent: February 24, 1998Assignee: Toray Industries, Inc.Inventors: Takao Tobe, Kanji Takahashi, Hiroshi Ohkuma, Masanobu Uyama
-
Patent number: 5718900Abstract: An immunogenic compound comprising the formula: ##STR1## wherein X is selected from the group consisting of methyl and hydrogen; wherein R.sub.1 is a suitable functional group of the lysergic ring;wherein R.sub.2 is an immunogenic protein; andwherein Y is a bridge to link R.sub.1 to R.sub.2.Purified polyclonal and monoclonal antibodies specifically reactive with the immunogenic compound and reactive with the lysergic ring of ergopeptine and clavine alkaloids are described. An antibody which is an anti-idiotype of the monoclonal antibody is provided. Methods of prevention and treatment of fescue toxicosis utilizing the immunogenic compounds and antibodies of the present invention are provided.Type: GrantFiled: October 20, 1994Date of Patent: February 17, 1998Assignee: University of Georgia Research Foundation, Inc.Inventors: Nicholas S. Hill, Frederick N. Thompson, Jr., John A. Stuedemann, Donald L. Dawe
-
Patent number: 5719193Abstract: This invention relates to a method of potentiating cell-mediated immunity which comprises administering to a patient a cell-mediated immunity potentiating amount of a compound of the formula:RHN--Z--NH--(CH.sub.2).sub.m --NH--Z--NHRor a pharmaceutically acceptable salt thereof, wherein m is an integer 3 to 12, Z is a saturated C.sub.2 -C.sub.6 alkylene moiety of straight or branched chain configuration, each R group is independently H, a C.sub.1 -C.sub.6 saturated or unsaturated hydrocarbyl, or --(CH.sub.2).sub.x --(Ar)--X wherein X is H, C.sub.1 -C.sub.6 alkoxy, halogen, C.sub.1 -C.sub.4 alkyl, or --S(O).sub.x R.sub.1, x is an integer 0, 1 or 2, and R.sub.1 is C.sub.1 -C.sub.6 alkyl.Type: GrantFiled: April 14, 1995Date of Patent: February 17, 1998Assignee: Merrell Pharmaceuticals, Inc.Inventors: Terry L. Bowlin, Nellikunja J. Prakash
-
Patent number: 5714140Abstract: This invention provides medical uses of a M-CSF, particularly a method and composition for treating inflammatory disease and allergy using natural M-CSF or recombinant M-CSF or the derivatives thereof.Type: GrantFiled: November 23, 1994Date of Patent: February 3, 1998Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Gideon Strassmann
-
Patent number: 5707616Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: October 4, 1996Date of Patent: January 13, 1998Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 5708025Abstract: Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.Type: GrantFiled: June 6, 1995Date of Patent: January 13, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Dvorit Samid
-
Patent number: 5705149Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.Type: GrantFiled: May 22, 1995Date of Patent: January 6, 1998Assignee: Sterling Winthrop Inc.Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
-
Patent number: 5702697Abstract: Damage to cells, tissue and other body parts in a mammalian host may be treated by using a colony stimulating factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.Type: GrantFiled: June 1, 1995Date of Patent: December 30, 1997Assignee: Chiron CorporationInventors: Robert Zimmerman, Benedict J. Marafino, Jr.
-
Patent number: 5702702Abstract: The invention provides a modified human cytotoxic T cell line, which is characterized by dual activity in vitro and in vivo against malignant cells and virus-infected cells. Also provided are effective and safe methods for use of the modified cells in adoptive therapy of cancer and untreatable vital diseases in MHC-mismatched recipients, and in marrow purging to achieve complete eradication of residual tumor cells from marrows of patients with leukemia and other types of cancer. Also provided are effective and safe methods for use of the cytokine stimulated, irradiated TALL-104 cells in the manufacture of a veterinary composition for adoptive therapy of canine and feline malignancies.Type: GrantFiled: June 6, 1995Date of Patent: December 30, 1997Assignee: The Wistar Institute of Anatomy and BiologyInventors: Daniela Santoli, Giovanni Rovera, Alessandra Cesano
-
Patent number: 5703088Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.Type: GrantFiled: June 4, 1992Date of Patent: December 30, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Richard J. Sharpe, Kenneth A. Arndt, Stephen J. Galli, Peter C. Meltzer, Raj K. Razdan, Howard P. Sard
-
Patent number: 5703060Abstract: Methods of prevention and treatment of infections and infestations in an animal by administering to the animal an effective amount of an acetylated mannan derivative.Type: GrantFiled: June 5, 1995Date of Patent: December 30, 1997Assignee: Carrington Laboratories Inc.Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
-
Patent number: 5700781Abstract: Prophylaxis against HIV, treatment for individuals infected with HIV, and treatment Kaposi's sarcoma can be effected, respectively, through the administration of human chorionic gonadotropin.Type: GrantFiled: November 10, 1994Date of Patent: December 23, 1997Inventor: Pamela Jo Harris
-
Patent number: 5700461Abstract: This invention provides a method for inhibiting HIV replication in a patient which comprises administering to a patient infected with HIV a therapeutically effective amount of IL-4.Type: GrantFiled: February 16, 1995Date of Patent: December 23, 1997Assignee: Schering CorporationInventor: Jerome Schwartz
-
Patent number: 5696081Abstract: The present invention comprises the method of selectively suppressing an immune response of a mammal to a particular alloantigen. The method includes several steps. One step is administering to a mammal an effective amount of UVB-radiation. Epidermal cell cultures, when subjected to UVA or UVB irradiation produce specific immunosuppressive factors. This UV-radiation is preferably UVA radiation (320 nm to 400 nm), or UVB-radiation (280 nm to 320 nm). It is demonstrated herein that UVA radiation results in in vitro cells producing a factor which selectively suppresses the CHS response in mammals, while UVB radiation selectively suppresses the DTH response in mammals. Another step of the inventive method involves desensitizing a mammal to a particular alloantigen. It has been determined that a mammal will become tolerant to a particular alloantigen once the subject mammal has been irradiated with a pre-determined wavelength of UVR and thereafter sensitized with the particular alloantigen.Type: GrantFiled: April 24, 1995Date of Patent: December 9, 1997Assignee: Board of Regents, The University Of Texas SystemInventor: Stephen E. Ullrich